Pyeon Dohun, Newton Michael A, Lambert Paul F, den Boon Johan A, Sengupta Srikumar, Marsit Carmen J, Woodworth Craig D, Connor Joseph P, Haugen Thomas H, Smith Elaine M, Kelsey Karl T, Turek Lubomir P, Ahlquist Paul
McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI 53706, USA.
Cancer Res. 2007 May 15;67(10):4605-19. doi: 10.1158/0008-5472.CAN-06-3619.
Human papillomaviruses (HPV) are associated with nearly all cervical cancers, 20% to 30% of head and neck cancers (HNC), and other cancers. Because HNCs also arise in HPV-negative patients, this type of cancer provides unique opportunities to define similarities and differences of HPV-positive versus HPV-negative cancers arising in the same tissue. Here, we describe genome-wide expression profiling of 84 HNCs, cervical cancers, and site-matched normal epithelial samples in which we used laser capture microdissection to enrich samples for tumor-derived versus normal epithelial cells. This analysis revealed that HPV(+) HNCs and cervical cancers differed in their patterns of gene expression yet shared many changes compared with HPV(-) HNCs. Some of these shared changes were predicted, but many others were not. Notably, HPV(+) HNCs and cervical cancers were found to be up-regulated in their expression of a distinct and larger subset of cell cycle genes than that observed in HPV(-) HNC. Moreover, HPV(+) cancers overexpressed testis-specific genes that are normally expressed only in meiotic cells. Many, although not all, of the hallmark differences between HPV(+) HNC and HPV(-) HNC were a direct consequence of HPV and in particular the viral E6 and E7 oncogenes. This included a novel association of HPV oncogenes with testis-specific gene expression. These findings in primary human tumors provide novel biomarkers for early detection of HPV(+) and HPV(-) cancers, and emphasize the potential value of targeting E6 and E7 function, alone or combined with radiation and/or traditional chemotherapy, in the treatment of HPV(+) cancers.
人乳头瘤病毒(HPV)几乎与所有宫颈癌、20%至30%的头颈癌(HNC)以及其他癌症相关。由于头颈癌也会出现在HPV阴性患者中,这种癌症类型为界定同一组织中HPV阳性与HPV阴性癌症的异同提供了独特机会。在此,我们描述了84例头颈癌、宫颈癌以及部位匹配的正常上皮样本的全基因组表达谱分析,其中我们使用激光捕获显微切割技术富集肿瘤来源细胞与正常上皮细胞样本。该分析表明,HPV(+)头颈癌和宫颈癌在基因表达模式上存在差异,但与HPV(-)头颈癌相比有许多共同变化。其中一些共同变化是可预测的,但许多其他变化并非如此。值得注意的是,发现HPV(+)头颈癌和宫颈癌中一个独特且更大的细胞周期基因子集的表达上调,高于HPV(-)头颈癌中的观察结果。此外,HPV(+)癌症过度表达通常仅在减数分裂细胞中表达的睾丸特异性基因。HPV(+)头颈癌和HPV(-)头颈癌之间的许多(尽管不是全部)标志性差异是HPV尤其是病毒E6和E7癌基因的直接后果。这包括HPV癌基因与睾丸特异性基因表达的新关联。原发性人类肿瘤中的这些发现为早期检测HPV(+)和HPV(-)癌症提供了新的生物标志物,并强调了单独或与放疗和/或传统化疗联合靶向E6和E7功能在治疗HPV(+)癌症中的潜在价值。